Document is current
Any future updates will be listed below
-
Authors
Grimes, Joseph M.
Shah, Nirav V.
Samie, Faramarz H.
Carvajal, Richard D.
Marr, Brian P.
- License Information
-
More Information
Article History
First Online: 21 January 2020
Compliance with Ethical Standards
:
: No external funding was used in the preparation of this manuscript.
: Joseph M. Grimes, Nirav V. Shah, and Faramarz H. Samie, M.D. declare that they have no conflicts of interests that might be relevant to the contents of this review. Brian P. Marr, M.D. provides consulting services for Aura Biosciences, Castle Biosciences, and Immunocore. Richard D. Carvajal, M.D. provides consulting services for Array, BMS, Castle Biosciences, Compugen, I-Mab, InxMed, Merck, Pierre Fabre, PureTech Health, Sanofi Genzyme, and Sorrento Therapeutics; is on scientific advisory boards for Aura Biosciences, Chimeron, and Rgenix; and receives research funding to Columbia University from Amgen, Array, Astellas, AztraZeneca, Bayer, Bellicum, BMS, Corvus, Eli Lilly, Ideaya, Immunocore, Incyte, Macrogenics, Merck, Mirati, Novartis, Pfizer, Plexxikon, and Roche/Genentech.
